Abnormal CTLA-4 function in T cells from patients with systemic lupus erythematosus. 2010

Elizabeth C Jury, and Fabian Flores-Borja, and Hardeep S Kalsi, and Mark Lazarus, and David A Isenberg, and Claudia Mauri, and Michael R Ehrenstein
Department of Medicine, Centre for Rheumatology, University College London, London, UK. e.jury@ucl.ac.uk

CTLA-4 is a critical gatekeeper of T-cell activation and immunological tolerance and has been implicated in patients with a variety of autoimmune diseases through genetic association. Since T cells from patients with the autoimmune disease systemic lupus erythematosus (SLE) display a characteristic hyperactive phenotype, we investigated the function of CTLA-4 in SLE. Our results reveal increased CTLA-4 expression in FOXP3(-) responder T cells from patients with SLE compared with other autoimmune rheumatic diseases and healthy controls. However, CTLA-4 was unable to regulate T-cell proliferation, lipid microdomain formation and phosphorylation of TCR-zeta following CD3/CD28 co-stimulation, in contrast to healthy T cells. Although lupus T cells responded in vitro to CD3/CD28 co-stimulation, there was no parallel increase in CTLA-4 expression, which would normally provide a break on T-cell proliferation. These defects were associated with exclusion of CTLA-4 from lipid microdomains providing an anatomical basis for its loss of function. Collectively our data identify CTLA-4 dysfunction as a potential cause for abnormal T-cell activation in patients with SLE, which could be targeted for therapy.

UI MeSH Term Description Entries
D008180 Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. Libman-Sacks Disease,Lupus Erythematosus Disseminatus,Systemic Lupus Erythematosus,Disease, Libman-Sacks,Libman Sacks Disease
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D005434 Flow Cytometry Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake. Cytofluorometry, Flow,Cytometry, Flow,Flow Microfluorimetry,Fluorescence-Activated Cell Sorting,Microfluorometry, Flow,Cell Sorting, Fluorescence-Activated,Cell Sortings, Fluorescence-Activated,Cytofluorometries, Flow,Cytometries, Flow,Flow Cytofluorometries,Flow Cytofluorometry,Flow Cytometries,Flow Microfluorometries,Flow Microfluorometry,Fluorescence Activated Cell Sorting,Fluorescence-Activated Cell Sortings,Microfluorimetry, Flow,Microfluorometries, Flow,Sorting, Fluorescence-Activated Cell,Sortings, Fluorescence-Activated Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013601 T-Lymphocytes Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen. T Cell,T Lymphocyte,T-Cells,Thymus-Dependent Lymphocytes,Cell, T,Cells, T,Lymphocyte, T,Lymphocyte, Thymus-Dependent,Lymphocytes, T,Lymphocytes, Thymus-Dependent,T Cells,T Lymphocytes,T-Cell,T-Lymphocyte,Thymus Dependent Lymphocytes,Thymus-Dependent Lymphocyte
D015496 CD4-Positive T-Lymphocytes A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes. T4 Cells,T4 Lymphocytes,CD4-Positive Lymphocytes,CD4 Positive T Lymphocytes,CD4-Positive Lymphocyte,CD4-Positive T-Lymphocyte,Lymphocyte, CD4-Positive,Lymphocytes, CD4-Positive,T-Lymphocyte, CD4-Positive,T-Lymphocytes, CD4-Positive,T4 Cell,T4 Lymphocyte
D015703 Antigens, CD Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation. CD Antigen,Cluster of Differentiation Antigen,Cluster of Differentiation Marker,Differentiation Antigens, Leukocyte, Human,Leukocyte Differentiation Antigens, Human,Cluster of Differentiation Antigens,Cluster of Differentiation Markers,Antigen Cluster, Differentiation,Antigen, CD,CD Antigens,Differentiation Antigen Cluster,Differentiation Marker Cluster,Marker Cluster, Differentiation
D017252 CD3 Complex Complex of at least five membrane-bound polypeptides in mature T-lymphocytes that are non-covalently associated with one another and with the T-cell receptor (RECEPTORS, ANTIGEN, T-CELL). The CD3 complex includes the gamma, delta, epsilon, zeta, and eta chains (subunits). When antigen binds to the T-cell receptor, the CD3 complex transduces the activating signals to the cytoplasm of the T-cell. The CD3 gamma and delta chains (subunits) are separate from and not related to the gamma/delta chains of the T-cell receptor (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA). Antigens, CD3,CD3 Antigens,T3 Antigens,CD3 Antigen,T3 Antigen,T3 Complex,Antigen, CD3,Antigen, T3,Antigens, T3
D051858 Forkhead Transcription Factors A subclass of winged helix DNA-binding proteins that share homology with their founding member fork head protein, Drosophila. Forkhead Box Protein,Forkhead Box Transcription Factor,Forkhead Protein,Forkhead Transcription Factor,Forkhead Box Proteins,Forkhead Box Transcription Factors,Forkhead Proteins,Fox Transcription Factors,Box Protein, Forkhead,Box Proteins, Forkhead,Factor, Forkhead Transcription,Protein, Forkhead,Protein, Forkhead Box,Proteins, Forkhead Box,Transcription Factor, Forkhead,Transcription Factors, Forkhead,Transcription Factors, Fox
D060908 CTLA-4 Antigen An inhibitory T CELL receptor that is closely related to CD28 ANTIGEN. It has specificity for CD80 ANTIGEN and CD86 ANTIGEN and acts as a negative regulator of peripheral T cell function. CTLA-4 antigen is believed to play role in inducing PERIPHERAL TOLERANCE. CTLA-4 Protein,Cytotoxic T-Lymphocyte Antigen 4,Antigens, CD152,CD152 Antigen,Cytotoxic T-Lymphocyte-Associated Antigen 4,Antigen, CD152,Antigen, CTLA-4,CD152 Antigens,CTLA 4 Antigen,CTLA 4 Protein,Cytotoxic T Lymphocyte Antigen 4,Cytotoxic T Lymphocyte Associated Antigen 4

Related Publications

Elizabeth C Jury, and Fabian Flores-Borja, and Hardeep S Kalsi, and Mark Lazarus, and David A Isenberg, and Claudia Mauri, and Michael R Ehrenstein
January 1999, Clinical and experimental rheumatology,
Elizabeth C Jury, and Fabian Flores-Borja, and Hardeep S Kalsi, and Mark Lazarus, and David A Isenberg, and Claudia Mauri, and Michael R Ehrenstein
January 2003, Clinical and experimental rheumatology,
Elizabeth C Jury, and Fabian Flores-Borja, and Hardeep S Kalsi, and Mark Lazarus, and David A Isenberg, and Claudia Mauri, and Michael R Ehrenstein
November 1998, Journal of clinical immunology,
Elizabeth C Jury, and Fabian Flores-Borja, and Hardeep S Kalsi, and Mark Lazarus, and David A Isenberg, and Claudia Mauri, and Michael R Ehrenstein
January 2003, Lupus,
Elizabeth C Jury, and Fabian Flores-Borja, and Hardeep S Kalsi, and Mark Lazarus, and David A Isenberg, and Claudia Mauri, and Michael R Ehrenstein
January 2009, Scandinavian journal of rheumatology,
Elizabeth C Jury, and Fabian Flores-Borja, and Hardeep S Kalsi, and Mark Lazarus, and David A Isenberg, and Claudia Mauri, and Michael R Ehrenstein
August 2016, Arthritis research & therapy,
Elizabeth C Jury, and Fabian Flores-Borja, and Hardeep S Kalsi, and Mark Lazarus, and David A Isenberg, and Claudia Mauri, and Michael R Ehrenstein
November 2021, International journal of rheumatic diseases,
Elizabeth C Jury, and Fabian Flores-Borja, and Hardeep S Kalsi, and Mark Lazarus, and David A Isenberg, and Claudia Mauri, and Michael R Ehrenstein
July 2006, Arthritis and rheumatism,
Elizabeth C Jury, and Fabian Flores-Borja, and Hardeep S Kalsi, and Mark Lazarus, and David A Isenberg, and Claudia Mauri, and Michael R Ehrenstein
January 2004, Arthritis and rheumatism,
Elizabeth C Jury, and Fabian Flores-Borja, and Hardeep S Kalsi, and Mark Lazarus, and David A Isenberg, and Claudia Mauri, and Michael R Ehrenstein
June 2006, The Journal of rheumatology,
Copied contents to your clipboard!